New Jersey Federal Judge Dismisses Patent Dispute Over Lysteda

(May 27, 2016, 2:07 PM EDT) -- TRENTON, N.J. — A patent infringement action involving an abbreviated new drug application (ANDA) covering generic tranexamic acid tablets was dismissed May 26 by a New Jersey federal judge (Ferring B.V. v. Watson Laboratories Inc., et al., No. 15-4222, D. N.J.; 2016 U.S. Dist. LEXIS 69328).

(Decision available. Document #16-160606-029Z.)

According to U.S. Judge Stanley R. Chesler of the District of New Jersey, the “artificial act of infringement” provision of the Hatch Waxman Act — codified at 35 U.S. Code Section 271(e)(2)(A) — “makes clear” that...
To view the full article, register now.